TNF-α: A POTENTIAL THERAPEUTIC TARGET FOR INFLAMMATORY BOWEL DISEASE Research Article

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• References Subscriptions Permissions Email Alerts Resistance of Crohn's Disease T Cells to Multiple Apoptotic Signals Is Associated with a Bcl-2/Bax Mucosal Imbalance

  2013cited by this paper
• Biologic Therapy for Inflammatory Bowel Disease

  2012cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma.

  2009cited by this paper
• TNFα blockade in human diseases: Mechanisms and future directions

  2008cited by this paper
• TNFα blockade in human diseases : An overview of efficacy and safety

  2008cited by this paper
• Targeting TNF-α: A novel therapeutic approach for asthma

  2008cited by this paper
• TNF‐mediated inflammatory disease

  2008cited by this paper
• TNFalpha blockade in human diseases: mechanisms and future directions.

  2008cited by this paper
• Immune dysfunction in inflammatory bowel disease.

  2007cited by this paper
• Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases

  2007cited by this paper
• The Role of TNFα in Ulcerative Colitis

  2007cited by this paper
• Anti-TNF Treatment in Inflammatory Bowel Disease

  2007cited by this paper
• A new transcription factor that regulates TNF‐&agr; gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC

  2006cited by this paper
• Respiratory Research BioMed Central Review Role of TNFα in pulmonary pathophysiology

  2006cited by this paper
• Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease

  2006cited by this paper
• Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.

  2005cited by this paper
• Oral methotrexate in ulcerative colitis

  2005cited by this paper
• The Met-196 → Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-α-induced Apoptosis by Impaired NF-κB Signaling and Target Gene Expression*

  2005cited by this paper
• Natalizumab induction and maintenance therapy for Crohn's disease.

  2005cited by this paper
• The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression.

  2005cited by this paper
• The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.

  2004cited by this paper
• Mechanisms of Natural Tolerance in the Intestine: Implications for Inflammatory Bowel Disease

  2004cited by this paper
• Emerging biologic therapies in inflammatory bowel disease.

  2004cited by this paper
• Importance of tumor necrosis factor-alpha cleavage process in post-transplantation lung injury in rats.

  2004cited by this paper
• Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.

  2004cited by this paper
• An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease

  2004cited by this paper
• Genetic and pathogenetic insights into inflammatory bowel disease

  2003cited by this paper
• Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease

  2003cited by this paper
• Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNFα-Mediated NF-κB Activation

  2003cited by this paper
• Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes.

  2003cited by this paper
• Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation.

  2003cited by this paper
• Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease

  2002cited by this paper
• Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors.

  2002cited by this paper
• Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease

  2002cited by this paper
• The current future understanding of inflammatory bowel disease.

  2002cited by this paper
• Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells.

  2001cited by this paper
• Tumor Necrosis Factor-α Induces Cyclooxygenase-2 Expression and Prostaglandin Release in Brain Microvessel Endothelial Cells

  2001cited by this paper
• Integrating anti–tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives

  2001cited by this paper
• The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha.

  2001cited by this paper
• The TNF and TNF Receptor Review Superfamilies: Integrating Mammalian Biology

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Role of cytokines in the pathogenesis of inflammatory bowel disease.

  2000cited by this paper
• Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

  2000cited by this paper
• Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment.

  2000cited by this paper
• Novel therapies for inflammatory bowel disease.

  1999cited by this paper
• Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.

  1999cited by this paper
• Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

  1999cited by this paper
• Synergistic effects of interferon γ and tumour necrosis factor α on T84 cell function

  1999cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

  1997cited by this paper
• Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha.

  1997cited by this paper
• Human immunodeficiency virus infection and Crohn's disease: the role of the CD4 cell in inflammatory bowel disease.

  1997cited by this paper
• Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

  1997cited by this paper
• Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells

  1997cited by this paper
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

  1997cited by this paper
• Treatment of ulcerative colitis with an engineered human anti‐TNFα antibody CDP571

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*)

  1996cited by this paper
• Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis

  1995cited by this paper
• Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

  1994cited by this paper
• Humanized antibodies.

  1993cited by this paper
• Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor.

  1993cited by this paper
• Pharmacokinetics and Metabolism of Therapeutic and Diagnostic Antibodies

  1992cited by this paper
• The pathophysiology of tumor necrosis factors.

  1992cited by this paper
• Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

  1992cited by this paper
• Humanised monoclonal antibody therapy for rheumatoid arthritis.

  1992cited by this paper
• Tumour necrosis factor‐alpha and interferon‐gamma production measured at the single cell level in normal and inflamed human intestine

  1990cited by this paper
• Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

  1989cited by this paper
• Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.

  1986cited by this paper
• An endotoxin-induced serum factor that causes necrosis of tumors.

  1975cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Histological And Biochemical Evaluation of the Effect of Topical Application of Curcumin And Propolis on oral Ulcer in Albino Rats

  2017cites this paper
• 2,4-Disubstituted thiazoles as multitargated bioactive molecules

  2016cites this paper
• Exploiting the role of various types of ion-channels against chemically induced inflammatory bowel disease in male Wistar rats

  2016cites this paper
• NANOCARRIERS FOR TARGETING IN INFLAMMATION

  2013cites this paper